| 纤溶酶原激活物抑制剂-1与心血管疾病 |
| |
| 引用本文： | 张冬梅,陈明. 纤溶酶原激活物抑制剂-1与心血管疾病[J]. 心血管病学进展, 2009, 30(4): 696-699 |
| |
| 作者姓名： | 张冬梅 陈明 |
| |
| 作者单位： | 重庆医科大学附属第一医院心内科,重庆,400016 |
| |
| 摘 要： | 纤溶酶原激活物抑制剂-1是纤溶系统的主要调节因子，通过抑制纽织型纤溶酶原活化剂影响血浆纤溶和凝血系统的平衡，引起或者加速心血管疾病的发生发展。纤溶酶原激活物抑制剂-1对心血管疾病的诊断、预后，尤其对冠心病的诊断、分型、危险分层、预后及经皮冠状动脉介入治疗后的再狭窄的判断有重要指导意义。心血管疾病相关的的辅助检查中，纤溶酶原激活物抑制剂-1将提供一种新的选择。
|
| 关 键 词： | 纤溶酶原激活物抑制剂-1 冠心病 原发性高血压 深静脉血栓形成 肺血栓栓塞 脑血栓形成 |
Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases |
| |
| ZHANG Dong-mei,CHENG Ming. Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases[J]. Advances in Cardiovascular Diseases, 2009, 30(4): 696-699 |
| |
| Authors: | ZHANG Dong-mei CHENG Ming |
| |
| Affiliation: | ZHANG Dong-mei, CHENG Ming ( Department of Cardiology, The First Hospital Affiliated to Chongqing Medical University, Chongqing 400016, China) |
| |
| Abstract: | Plasminogen Activator Inhibitor-1 （ PAI-1 ） is a primary regulator of the fibrinolytic system. It is becoming a recognized risk factor in the development of cardiovascular diseases through its inhibition of the effects of t-PA. PAI-1 is also very important in the diagnosis and the risk stratification of coronary heart disease. PAI-1 may provide a new option in the auxiliary examination of cardiovascular diseases. |
| |
| Keywords: | plasminogen activator inhibitor-1 coronary heart disease primary hypertension deep vein thrombosis pulmonary thromboembolism cerebral thrombosis |
| 本文献已被 维普 万方数据 等数据库收录！ |
